Compare Fox Corp Class B (FOX) vs Johnson & Johnson (JNJ) Price & Performance

FOX trades at $49.50, down 1.43% today, with technical indicators showing a neutral to bearish short-term bias. The company demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $1.32 versus $0.988, continuing a trend of earnings surprises. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. Analyst sentiment is mixed with 43% buy ratings but technical weakness persists near key support levels.

The outlook remains cautiously optimistic given FOX's consistent earnings beats and improved cash flow generation, though technical weakness and competitive pressures in media streaming present near-term challenges. The stock offers reasonable valuation with P/E of 13.26x, but investors should monitor advertising trends and Roku integration execution risks.

Johnson & Johnson (JNJ) trades at $253.85, down 1.52% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 earnings of $2.70 per share, beating estimates, and raised its full-year 2026 outlook. Revenue grew 6.6% annually in Q2 2026, driven by strength in Innovative Medicine and new product launches, though MedTech sales slightly missed expectations.

JNJ offers a compelling investment case with a 64-year dividend king status, robust profitability, and raised guidance, but faces risks from patent expirations and competitive pressures. Analyst consensus is bullish with a $281 price target, suggesting ~11% upside, supported by strong institutional confidence and innovation in AI and robotics targeting $100 billion revenue.